Skip to main content
PMC home page
PLOS ONE logoLink to PLOS ONE
. 2017 Nov 10;12(11):e0187865. doi: 10.1371/journal.pone.0187865

Inconsistent selection of outcomes and measurement devices found in shoulder arthroplasty research: An analysis of studies on ClinicalTrials.gov

Matthew Thomas Sims 1,*, Byron Nice Detweiler 1, Jared Thomas Scott 1, Benjamin McKinnley Howard 1, Grant Richard Detten 1, Matt Vassar 1
Editor: John Leicester Williams2
PMCID: PMC5681263  PMID: 29125866

Abstract

Introduction

Recent evidence suggests a lack of standardization of shoulder arthroplasty outcomes. This issue is a limiting factor in systematic reviews. Core outcome set (COS) methodology could address this problem by delineating a minimum set of outcomes for measurement in all shoulder arthroplasty trials.

Methods

A ClinicalTrials.gov search yielded 114 results. Eligible trials were coded on the following characteristics: study status, study type, arthroplasty type, sample size, measured outcomes, outcome measurement device, specific metric of measurement, method of aggregation, outcome classification, and adverse events.

Results

Sixty-six trials underwent data abstraction and data synthesis. Following abstraction, 383 shoulder arthroplasty outcomes were organized into 11 outcome domains. The most commonly reported outcomes were shoulder outcome score (n = 58), pain (n = 33), and quality of life (n = 15). The most common measurement devices were the Constant-Murley Shoulder Outcome Score (n = 38) and American Shoulder and Elbow Surgeons Shoulder Score (n = 33). Temporal patterns of outcome use was also found.

Conclusion

Our study suggests the need for greater standardization of outcomes and instruments. The lack of consistency across trials indicates that developing a core outcome set for shoulder arthroplasty trials would be worthwhile. Such standardization would allow for more effective comparison across studies in systematic reviews, while at the same time consider important outcomes that may be underrepresented otherwise. This review of outcomes provides an evidence-based foundation for the development of a COS for shoulder arthroplasty.

1 Introduction

Orthopedic shoulder pathology from age-related complications is increasing, due in part to longer lifespans. Osteoarthritis and rotator cuff disease are two degenerative conditions most commonly identified as causing pain and disability in the aging population [1]. While many treatments exist for initial stages of degenerative shoulder diseases, three interventions are most common for treatment of progressive to severe osteoarthritis. Total shoulder arthroplasty (TSA)—replacement of the humeral head and prosthetic resurfacing of the glenoid—is considered the gold standard treatment due to its reliable pain relief, predictable improvement of function, and enhanced quality of life [2–4]. Hemiarthroplasty (HA), which involves replacing the humeral head alone [1], and reverse shoulder arthroplasty (RSA), a modified TSA where the semi-circumference ball is implanted in the glenoid and a stem with a concave polyethylene cap implanted in the humerus, are also viable treatments for advanced shoulder disease. Exponential increases in use of these interventions warrant further study to better understand their efficacy, surgical indications, and potential complications [5–7]. Unfortunately, useful information on these aspects of shoulder arthroplasty is limited, partially due to methodological issues associated with the reported studies. For instance, a Cochrane systematic review of these surgeries for shoulder osteoarthritis was inconclusive, in part, because the primary studies comprising the review did not measure outcomes aligned with the research questions [8]. In fact, most outcomes important to the systematic reviewers were measured in only a single study. Another recent review of arthroscopy following shoulder arthroplasty noted significant heterogeneity in outcome reporting among primary studies which limited the reviewers’ ability to perform a quantitative synthesis of outcomes [9]. Standardization of outcomes for shoulder arthroplasty studies would help overcome limitations reported in previous systematic reviews and allow for more conclusive evaluations of efficacy.

Core outcome set (COS) methodology could address this problem using consensus approaches involving trialists, systematic reviewers, funders, patients, and other research stakeholders to derive a minimum set of outcomes for measurement across shoulder arthroplasty studies [10–12]. In conjunction with COS development, core outcome measurement sets establish the instruments that should be administered for outcome measurement [13]. For example, there are currently several shoulder measures available: the American Shoulder and Elbow Surgeons Society Standardized Shoulder Assessment Form (ASES), the Constant-Murley Shoulder Outcome Score, Disabilities of the Arm, Shoulder, and Hand Questionnaire (DASH), the QuickDASH, L’Insalata Shoulder Rating Questionnaire, Simple Shoulder Test (SST), the Oxford Shoulder Score (OSS), the Shoulder Disability Questionnaire (SDQ), and the Western Ontario Shoulder Instability Index (WOSI), among others [14,15]. Whether condition-specific symptoms should be limited to movement-related shoulder functions or more generally to include broader aspects of functioning (e.g., leisure activities or work) remains a source of debate [16] and the diversity of items and domains comprising such measures may impede meta-analytic investigations. A standardized recommendation for evaluation of shoulder function would improve the ability to synthesize evidence across studies. Given the impressive growth of TSA, HA, and RSA procedures, there is a need for continued evaluation of their efficacy and for determining whether an increased standardization of outcomes is necessary. Here, we conduct an analysis of shoulder arthroplasty intervention studies registered on ClinicalTrials.gov to elucidate the diversity of methodologies and outcomes reported. The objective of this study is to provide an evidence-based foundation for the development of a COS for shoulder arthroplasty.

2 Methods

We conducted an analysis of studies catalogued in ClinicalTrials.gov to examine outcomes reported in registered orthopedic surgery clinical trials. This study did not meet the regulatory definition of human subject research as defined in 45 CFR 46.102(d) and (f) of the Department of Health and Human Services’ Code of Federal Regulations [17] and, therefore, was not subject to Institutional Review Board oversight. We consulted Li et al [18], the Cochrane Handbook for Systematic Reviews of Interventions [19], and the National Academies of Science, Engineering, and Medicine’s (formally the Institute of Medicine) Standards for Systematic Reviews [20] for best practices in data collection and management for systematic reviews as we developed our methodology. To adhere to best practices in reporting, we applied relevant PRISMA guidelines [21] (Checklist items 1–3, 5–11, 13, 16–18, 20, 23, 24, 26, 27) since our study involved the synthesis of multiple registered trials. We applied SAMPL guidelines [22] for reporting descriptive statistics. This study was registered with the Core Outcome Measurement in Effectiveness Trials (COMET) Initiative (http://www.comet-initiative.org/studies/details/812?result=true). Data from this study is publicly available on figshare (https://dx.doi.org/10.6084/m9.figshare.3464831.v2).

2.1 Eligibility criteria for considering studies for this review

Primary studies registered in ClinicalTrials.gov between 2005 and 2015 in which shoulder arthroplasty (including total shoulder arthroplasty, reverse shoulder arthroplasty, hemiarthroplasty, and glenoid resurfacing) was used as an intervention were eligible for this review. For this study, both open (not yet recruiting, recruiting) and closed (active, not recruiting; completed; terminated; suspended; withdrawn; enrolling by invitation) trials were eligible for inclusion. Randomized and non-randomized clinical trials as well as observational studies were included since these study designs may be registered on ClinicalTrials.gov [23]. We used the following definitions to classify study types. A clinical trial (National Institutes of Health definition) was defined as “a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.” An observational study was defined as “a biomedical or behavioral research study of human subjects designed to assess risk factors for disease development or progression, assess natural history of risk factors or disease, identify variations based on geographic or personal characteristics (such as race/ethnicity or gender), track temporal trends, or describe patterns of clinical care and treatment in absence of specific study-mandated interventions” [24].

2.2.1 Search strategy for identifying relevant studies

We consulted a research librarian to conduct a search for clinical trials registered on ClinicalTrials.gov that examined shoulder arthroplasty interventions reported in orthopedic surgery literature. ClinicalTrials.gov was searched in order to identify unpublished or ongoing trials. We used registered trials to minimize the possibility of selective outcome reporting bias30 and to better understand the outcomes reported in current orthopedic clinical trials. This search was narrowed for four common arthroplasty shoulder procedures: total shoulder arthroplasty (TSA), reverse shoulder arthroplasty (RSA), hemiarthroplasty (HA), and glenoid resurfacing; however, we did not impose a limiter for language or restrict the search by journal. The final search string is as follows: Shoulder AND (Surg* OR operat* OR arthroplasty OR hemiarthroplasty OR (joint* AND replace*) OR debride OR debridement OR debrided OR (surface AND (replace OR replacement OR replaced)) OR resurface OR resurfaced OR resurfacing) | received from 01/01/2005 to 12/31/2016. The search was performed on June 30, 2017.

2.2.2 Study selection and data collection

Four authors (MTS, JTS, BMH, and GRD) equally divided the studies among one another and independently screened all of the studies for eligibility. To be eligible, a study must have reported the use of shoulder arthroplasty as an intervention. We included total, hemi-, and reverse arthroplasty as well as glenoid resurfacing; hence, arthroscopic studies were excluded from analysis. Studies must also have been registered on ClinicalTrials.gov between 2000 and 2016. We included both observational and interventional studies, as both commonly report primary and secondary outcomes in ClinicalTrials.gov. After the initial screening was completed, a second screening was performed by an author (BND) who was blinded from previous screening results. Discrepancies in screening were resolved by discussion between BND and the other authors. Final exclusions are outlined in the PRISMA flow diagram (Fig 1).

Fig 1. PRISMA flowchart.

Fig 1

Open in a new tab

PRISMA flowchart displaying the search results along with the included and excluded studies.

An abstraction manual was designed after consulting several sources [25–30] to ensure data abstraction was consistently and accurately performed by authors. Authors participated in a series of meetings to apply the abstraction manual to a subset of 15 studies as a pilot test before launch. During these meetings, authors abstracted data elements by reviewing each study, discussing data elements, and reaching agreement on changes to the abstraction manual. Refinements were made based on pilot feedback and a final manual was produced. Data elements included:

  • sponsor(s), title of the article;

  • start date of trial (year);

  • study status (not yet recruiting; recruiting; active, not recruiting; completed; terminated; suspended; withdrawn; enrolling by invitation)

  • study type (interventional, observational, etc.);

  • type of arthroplasty (TSA, RSA, HA, glenoid resurfacing, other);

  • sample size;

  • measured outcomes;

  • outcome measurement device;

  • specific metric of measurement (value at a time point, change from baseline, time to event, unclear);

  • method of aggregation (mean, median, percent/proportion, absolute number, unclear);

  • outcome classification (primary, secondary, other, unclear);

  • whether the outcome was considered a side effect/harmful.

The registered studies meeting inclusion criteria were then equally divided for data abstraction among four authors (MTS, GRD, JTS, and BMH). Working in pairs, authors first abstracted data elements from articles in their set and then validated the abstracted data of their partner. Any discrepancies in data abstraction were settled by discussion between the pair, or when necessary, by adjudication with the blinded author (BND) to ensure the accuracy and integrity of this study.

2.3 Definition and classification of measured outcomes

We defined an outcome as the exact word-for-word terms (presented as either a primary or secondary outcome) in a trial for any clinical endpoint, or physiological, metabolic, or mortality event measured by clinicians or researchers [26]. Eleven outcome domains were determined based on the distribution of outcomes within this study and previously defined domains by Page et al [28]. Outcomes were classified under the following outcome domains: Adverse Events, Function/Disability, Global Assessment of Treatment Success, Health Related Quality of Life (HRQoL), Orthopedic Tests, Other, Pain, Radiologic Evaluation, Range of Motion (ROM), Strength, and Survival. Individual outcomes were distributed into each of these categories during the coding process. In order to decrease heterogeneity of reported outcomes, authors determined standardized terminology for each outcome.

2.4 Statistical analysis

Results were summarized using frequencies and percentages for binary outcomes, and medians and interquartile ranges (IRQs) for continuous outcomes. Locally weighted scatterplot smoothing (nonparametric regression method) was used to smooth the scatterplots of outcome domain use over time [28]. Our final scatterplot data is available on figshare (https://dx.doi.org/10.6084/m9.figshare.3464831.v2). Descriptive statistics were used to summarize data and all analyses were conducted using STATA 13.1 (College Station, TX).

3 Results

A total of 114 clinical trials were identified on ClinicalTrials.gov. Forty-eight studies were excluded after failing to meet inclusion criteria (Fig 1). A final sample size of 66 trials underwent data abstraction and was included in the final data synthesis. Clinical trials included within this study started their research between 2000 and 2016, as summarized in Table 1.

Table 1. Characteristics of included studies (Updated to Reflect 2016 Data).

Characteristics Number (%) of trials (n = 66)
Start Date of Trial
    2000–2004 6 (9.1)
    2005–2008 13 (19.7)
    2009–2012 20 (30.3)
    2013–2016 27 (40.9)
Phase of Trial
    Active, Not Recruiting 10 (15.2)
    Completed 14 (21.2)
    Enrolling by Invitation 6 (9.1)
    Not yet Recruiting 3 (4.5)
    Recruiting 18 (27.3)
    Suspended 1 (1.5)
    Terminated 4 (6.1)
    Unknown 9 (13.6)
    Withdrawn 1 (1.5)
Type of Trial
    Interventional 37 (56.1)
    Observational 29 (43.9)
Procedure Frequency
    Hemiarthroplasty (HA) 15 (16.9)
    Total Shoulder Arthroplasty (TSA) 37 (41.6)
    Reverse Shoulder Arthroplasty (RSA) 24 (27)
    Glenoid Resurfacing 11 (12.3)
    Other 2 (2.2)
Open in a new tab

3.1 Summary of shoulder arthroplasty trials characteristics

Nearly half of the studies were comprised of “Completed” (14/66, 21.2%) and “Recruiting” (18/66, 27.3%) studies. “Active, not recruiting” and “Unknown” trials each accounted for 10 and 9, respectively, (19/66, 28.8%) of the remaining trials (Table 1). Of the 66 studies, 37 were listed as interventional (37/66, 56.1%) and 29 were listed as observational (29/66, 43.9%). The most frequently reported shoulder arthroplastic procedure was TSA (37/66, 41.6%). RSA (24/66, 27%), HA (15/66, 16.9%), and glenoid resurfacing (11/66, 12.3%) were also commonly reported shoulder arthroplasties (Table 1).

3.2 Shoulder arthroplasty outcomes and domain categories

Following data abstraction, 383 shoulder arthroplasty outcomes were organized into 11 different outcome domains. The standardized outcomes, measurement devices and specific metrics were summarized and organized into domain categories, as displayed in Table 2.

Table 2. Domain categories and reported outcomes, device, and metric within each domain (Updated to Reflect 2016 Data).

Domains (n = 11) Outcomes (n = 383) Measurement Devices Specific Metric
Adverse Events
(n = 25) 		Adverse events (7)
Device associated adverse events (3)
Biceps rupture (1)
Device migration (1)
Intraoperative bleeding (1)
Intraoperative neurovascular injury (1)
Intraoperative prosthetic fracture (1)
Lack of unanticipated device related serious
adverse events (1)
Osteolysis (1)
Postoperative bleeding (1)
Postoperative infection (1)
Postoperative instability (1)
Procedure associated adverse events (2)
Revision complications (1)		 Frequency (19)
Unspecified (3)		 Value at a time point (20)
Unspecified (2)
Function/Disability
(n = 16) 		Function (15)
Function/disability (1)		 ASES (4)
SST (4)
Constant (3)
SANE (2)
Clinical outcome comparison (1)
Unspecified (1)
VAS (1)		 Value at a time point (13)
Change from baseline (3)
Global Assessment of Treatment Success
(n = 60) 		Shoulder outcome score (58)
Effectiveness (1)
Impact of arm length difference on patient
reported outcome (1)		 Constant (2)
ASES (19)
Oxford (5)
PENN (3)
DASH (3)
QuickDASH (3)
SSV (2)
Modified Constant (1)
Neer’s limited goals (1)
SANE (1)
SPADI (1)
UCLA (1)		 Value at a time point (42)
Change from baseline (12)
Health Related Quality of Life
(n = 68) 		Quality of life (15)
Multidimensional aspects of health (8)
Patient satisfaction (9)
Activities of daily living (4)
Disease or joint specific measure (4)
General health component (2)
Patient objective data (2)
Patient subjective data (2)
Anxiety/depression (1)
Mental component summary (1)
Mental health component (1)
Mobility (1)
Personal dependency status (1)
Physical component summary (1)
Physical function (1)
Role emotional (1)
Role physical (1)
Self-care (2)
Social function (1)
Usual activities (1)
VAS (1)
Vitality (1)
Willingness to have surgery performed again (1)		 EQ5D (11)
SF-36 (10)
WOOS (8)
SF-12 (6)
Unspecified (6)
ASES (2)
EQ5D5L (2)
Patient assessment forms (2)
VAS (2)
15D (2)
ADLER (1)
SPADI (1)
Unspecified (1)
PENN (1)
4-point rating (1)
Constant (1)
DASH (1)
Quality of life survey (1)
SST (1)		 Value at a time point (39)
Change from baseline (20)
Unspecified (1)
Orthopedic Tests
(n = 7) 		Test specific outcomes (4)
Integrity & function of subscapularis tendon (2)
Internal rotation extension (1)		 Abdominal compression test (2)
Lift off test (2)
Hornblower’s test (1)
Speed’s test (1)
Yergason’s test (1)		 Change from baseline (5)
Value at a time point (2)
Other
(n = 23) 		Cost association (1)
Health economics (1)
Recovery time (1)
Surgical time (1)		 Unspecified (3)
Health resource utilization instrument (1)		 Value at a time point (4)
Pain
(n = 35) 		Pain (33)
Pain at rest (1)
Pain with active motion (1)
Pain/discomfort (2)
Pain/weakness (1)
Preoperative pain (1)		 VAS (10)
ASES (6)
NRS (3)
Unspecified (3)
SANE (2)
Clinical outcome comparison (1)
Constant (2)
SF-36 (1)
SPADI (1)
EQ5D (1)
PENN (1)
Likert scale (1)		 Value at a time point (21)
Change from baseline (6)
Radiologic Evaluation
(n = 79) 		Acromiohumeral interval (1)
Actual versus optimal glenosphere position (1)
Actual versus predicted scapular notching (1)
Bone density around the prosthesis (1)
Bony apposition (2)
Bony integration of the component (1)
Clinical outcome comparison (1)
Component loosening (3)
Component position (1)
Coracoid to glenohumeral joint distance (1)
Coracoid to tuberosity distance (1)
Correlation between bone density and prosthesis
migration (1)
Cumulative incidence of migration, radiolucency, osteolysis, and bone wear (1)
Decreased component loosening (2)
Decreased radiolucent lines (2)
Determine if the use of autologous bone graft around the anchor-peg glenoid prosthesis correlate with
bony apposition (1)
Determine if the use of autologous bone graft around the anchor-peg glenoid prosthesis correlate with decreased radiolucent lines and component loosening (1)
Determine if the use of autologous bone graft around the anchor-peg glenoid prosthesis correlate with functional outcomes (1)
Difference in component migration between conventional and lateralized glenoid components (1)
Evidence of movement or pending failure (1)
Fixation to bone/early migration of the implants (1)
Function (2)
Glenoid component migration (1)
Glenoid component position (3)
Glenoid erosion (3)
Glenoid status (2)
Head to tuberosity distance (1)
Humeral congruity (1)
Humeral cortical thickness (1)
Humeral stem position–valgus/varus (1)
Humeral subluxation (1)
Lateralization index (3)
Location and placement of HRA device (1)
Radiographic evaluation (3)
Migration between cemented and press-fit RTSA humeral components (1)
Migration of resurfacing prosthesis (1)
No evidence of device failure (1)
Postoperative clinical results (1)
Qualitative documentation of surgical steps (1)
Radiographic failure (1)
Radiolucent lines (5)
Scapular notching (1)
Subacromial space (3)
Subsidence (5)
Tuberosity thinning (3)
X-Rays (3)		 Radiograph (21)
3D CT (2)
Unspecified (13)
CT (12)
Millimeters (2)
Frequency (1)
Radiostereometric analysis (3)
Degrees (1)
Plain radiograph (2)
MRI (7)
X-Ray (9)
Modified Tingart & Al method (1)
Intraoperative photographs (1)		 Value at a time point (61)
Change from baseline (13)
Unspecified (1)
Range of Motion
(n = 38) 		Range of motion (11)
External rotation (4)
Internal rotation (3)
Active external rotation (2)
Flexion (2)
Passive external rotation (2)
Active abduction (1)
Active flexion (1)
Active internal rotation (1)
Active range of motion (1)
Passive abduction (1)
Passive flexion (1)
Passive internal rotation (1)
Passive range of motion (1)
Postoperative clinical results (1)
Scaption (1)		 Constant (10)
Unspecified (17)
Goniometer (4)
Range of motion (1)
ASES (1)
Degrees (1)		 Change from baseline (21)
Value at a time point (13)
Strength
(n = 16) 		External rotation strength (2)
Flexion strength (2)
Internal rotation strength (2)
Strength (2)
External abduction strength (1)
Scapula abduction strength (2)
Thumb down abduction strength (1)		 Pounds (5)
Lafayette manual muscle testing system (4)
Iso-force machine (2)
Unspecified (1)		 Value at a time point (10)
Change from baseline (2)
Survival
(n = 16) 		Implant survival (11)
Revision/reoperation (3)
Device success rate (1)
Time to first revision (1)		 Frequency (6)
Kaplan-Meier (5)
Unspecified (5)		 Time to event (11)
Value at a time point (4)
Unspecified (1)
Open in a new tab

The Radiologic Evaluation domain contained the greatest number of outcomes (n = 79) followed by the HRQoL (n = 68) and Global Assessment of Treatment Success (n = 60) domains (Table 2). In terms of outcome reporting, the Radiologic Evaluation domain contained a large number of unique outcomes that were measured in a few studies. The Global Assessment of Treatment Success domain contained the most commonly reported outcome, shoulder outcome score (n = 58). Pain (n = 33), quality of life (n = 15), function (n = 15), ROM (n = 11) and implant survival (n = 11) were also frequently reported outcomes (Table 3). Across all domains, 61 outcomes had an unspecified measurement device. The most common measurement devices were the Constant-Murley Shoulder Outcome Score (n = 38), American Shoulder and Elbow Surgeons (ASES) Shoulder Score (n = 33), and frequency counts (such as number of adverse events or revisions) (n = 30) (Table 2).

Table 3. Outcomes reported by frequency of measurements (Updated to Reflect 2016 Data).

Outcomes reported in >5 studies
Adverse events Function Implant Survival Multidimensional aspects of health
Pain Patient satisfaction Range of motion Shoulder outcome score
Quality of life
Outcomes reported in 2–5 studies
Active external rotation Activities of daily living Bony apposition Component loosening
Decreased component loosening Decreased radiolucent lines Device associated adverse events Disease or joint specific measure
External rotation External rotation strength Flexion Flexion strength
General health component Glenoid component position Glenoid erosion Glenoid status
Integrity & function of subscapular tendon Internal rotation Internal rotation strength Lateralization index
Passive external rotation Patient objective data Patient subjective data Postoperative clinical results
Radiographic evaluation Radiolucent lines Revision/reoperation Scapula abduction strength
Strength Subacromial space Subsidence Test specific outcomes
Tuberosity thinning X-Rays
Outcomes reported only once
Acromiohumeral interval Active abduction Active flexion Active internal rotation
Active range of motion Actual versus optimal glenosphere position Actual versus predicted scapular notching Anxiety/depression
Biceps rupture Bone density around the prosthesis Bony integration of the component Clinical outcome comparison
Component position Coracoid to glenohumeral joint distance Coracoid to tuberosity distance Correlation between bone density and prosthesis migration
Cost association Cumulative incidence of migration, radiolucency, osteolysis, and bone wear Determine if the use of autologous bone graft around the anchor-peg glenoid prosthesis correlate with decreased radiolucent lines and component loosening Determine if the use of autologous bone graft around the anchor-peg glenoid prosthesis correlate with functional outcomes
Determine if the use of autologous bone graft around the anchor-peg glenoid prosthesis correlate with
bony apposition		 Device migration Device success rate Difference in component migration between conventional and lateralized glenoid components
Effectiveness
 Evidence of movement or pending failure External abduction strength
 Fixation to bone/early migration of the implants
Function/disability Glenoid component migration Head to tuberosity distance Health economics
Humeral congruity Humeral cortical thickness Humeral stem position-valgus/varus Humeral subluxation
Impact of arm length difference on patient reported outcome Internal rotation extension Intraoperative bleeding Intraoperative neurovascular injury
Intraoperative prosthetic fracture Lack of unanticipated device related serious adverse events Location and placement of HRA device Mental component summary
Mental health component
 Migration between cemented and press-fit RTSA humeral components Migration of resurfacing prosthesis Mobility
No evidence of device failure Osteolysis Pain at rest Pain with active motion
Pain/discomfort Pain/weakness Passive abduction Passive flexion
Passive internal rotation Passive range of motion Personal dependency status Physical component summary
Physical function Postoperative bleeding Postoperative infection Postoperative instability
Preoperative pain Procedure associated adverse events Qualitative documentation of surgical steps Radiographic failures
Recovery time Revision complications Role emotional Role physical
Scaption Scapular notching Self-care Social function
Surgical time Thumb down abduction strength Time to first revision Usual activities
Visual analog scale Vitality Willingness to have surgery performed again
Open in a new tab

There was a mean of six outcomes reported per study, with a range between one and thirty-seven outcomes reported per study. In each trial registry, the outcomes received a classification of primary, secondary, other, or unspecified. Of the 383 reported outcomes, 68.7% (263/383) were classified as secondary outcomes and the remaining were predominantly primary outcomes (120/383, 31.3%).

3.3 Frequency of outcome domains over time

The frequency of reported outcomes over time is shown in Fig 2. Solid lines are smoothed values calculated from the nonparametric regression locally weighted scatterplot smoothing method (LOWESS). Visual inspection of the smoothed scatterplots indicates the survival outcome domain showed a trend of an overall increase from 2000 to 2016 while the pain outcome domain showed an increase following a significant decrease in reporting prior to 2005. The orthopedic tests and strength domains remained stable over time while global assessment of treatment success domain maintained a stable decline in outcome reporting over time (Fig 2).

Fig 2. Smoothed scatterplots of outcome domain use over time.

Fig 2

Open in a new tab

The frequency of reported outcomes over time are shown in these nonparametric regression locally weighted scatterplot smoothing method (LOWESS).

4 Discussion

Results from our study suggest the need for greater standardization of outcomes as well as the instruments used to measure them. Interestingly, concurrent evaluations to ours by Page et al. [31–32] have affirmed the need for greater standardization of outcomes and measurement for shoulder disorders. Our findings are complimentary and confirmatory even though we used different search methodologies and applied different inclusion criteria. We limited our search to registered trials to minimize selective outcome reporting, whereas Page et al. reviewed published trials that served as primary studies in Cochrane reviews or were indexed in PubMed. Furthermore, while we examined outcomes reported across studies applying specific interventions (i.e., arthroplastic procedures), Page et al. looked more broadly at shoulder disorders. Despite these differences, we observed similar inconsistencies in trial outcomes. The lack of consistency observed in these studies indicates that developing a core outcome set for shoulder arthroplasty trials would be worthwhile. Such standardization would allow for more effective study to study comparisons in systematic reviews, while at the same time consider important outcomes that may be underrepresented otherwise.

While six outcomes, on average, were measured across trials, there were trials with as many as 37 outcomes measured in a single trial. Core outcome sets are developed to refine outcomes to those most meaningful and important across investigations and could help limit the number of outcomes being measured. Large numbers of outcomes in trials could result in increased occurrences of selective outcome reporting bias [33] or p-hacking [34], both of which may adversely affect our understanding of the true nature of clinical trial results.

We found a wide variety of shoulder instruments used across trials. For global assessment of treatment success, the Constant-Murley Score and ASES were used more frequently than other instruments. A systematic review of psychometric properties for the Constant-Murley Score reported the need for greater standardization for performing the score and greater caution during score interpretation [35]. Other issues, such as weighting the subscales, are ongoing matters of investigation with this scale. For most shoulder instruments, psychometric studies have focused on traditional validity and reliability estimates. Additional research is needed to determine important outcomes such as the minimal clinically important difference [35,36].

We noted several temporal trends in outcomes in this study. For example, our results suggest that HRQoL outcomes decreased over time. This finding is contrary to recent calls to include patient-centered outcomes in clinical research [37–41]. As early as 1990s, researchers recognized the importance of including patient-centered outcomes in orthopedic surgery research, rather than reliance on revision rates or clinical judgments to evaluate post-operative improvement [42]. Xu et al described HRQoL outcomes as a “necessity to fully understand the effects” of orthopedic interventions [43]. Furthermore, given recent indications of the prevalence of clinical depression in patients undergoing elective TSA, improved understanding of important quality of life variables is clearly warranted [44].

5 Limitations

Our study has the following limitations. We limited our sample to outcomes reported on ClinicalTrials.gov based on the recommendation of Clark and Williamson [45]. We chose this approach to include the most current outcomes, while simultaneously limiting selective outcome reporting bias. Although ClinicalTrials.gov is a United States based trial registry platform, there are currently 201 countries utilizing the registry and accounting for nearly 50% of registered studies [46]. Challenges also exist with registry-listed outcomes, which include the potential for vague and incomplete reporting. These challenges have been noted by the WHO and ClinicalTrials.gov, and actions are being taken to improve the accurate reporting of trial outcomes. We also did not search other trial registries, as Moja et al found that ClinicalTrials.gov contained enough data to adequately describe the ongoing research and was most valuable of all registries to finding ongoing clinical trials [47]. Furthermore, we wanted to avoid translating registrations that were written in other languages. We also did not search databases of published works, like MEDLINE or Embase, since published studies have been known to limit outcome reporting to only those which were found to be statistically significant [48–50]; therefore, the published literature may not contain all outcomes originally intended for measurement [51].

6 Conclusion

In summary, this study found a lack of standardization regarding outcomes and measurement devices. This lack of standardization limits systematic reviews to outcomes reported and measured consistently across studies. Important outcomes may be omitted from a subset of studies, limiting data synthesis. Our study provides a summary of outcomes most frequently reported and co-occurring outcomes as a foundation for a follow up study to begin developing a core outcome set for shoulder arthroplasty studies.

Supporting information

S1 File. PRISMA checklist.

(DOC)

Click here for additional data file. (63KB, doc)

Data Availability

Data from this study is publicly available on figshare (https://dx.doi.org/10.6084/m9.figshare.3464831.v2).

Funding Statement

The authors received no specific funding for this work.

References

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 File. PRISMA checklist.

(DOC)

Click here for additional data file. (63KB, doc)

Data Availability Statement

Data from this study is publicly available on figshare (https://dx.doi.org/10.6084/m9.figshare.3464831.v2).

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES